Trials / Completed
CompletedNCT02804178
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Millendo Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and efficacy of orally administered ATR-101 in subjects with classic congenital adrenal hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to 6 months per subject. A subject may receive a minimum of one dose level or up to a maximum of 5 dose levels, in sequentially increasing dose strengths. Each dose level will last 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATR-101 | 125-1000 mg twice per week |
Timeline
- Start date
- 2016-05-18
- Primary completion
- 2017-08-17
- Completion
- 2017-08-17
- First posted
- 2016-06-17
- Last updated
- 2021-03-10
- Results posted
- 2021-02-17
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02804178. Inclusion in this directory is not an endorsement.